The Brand Name REDITUX RA Has Generic Salt :: RITUXIMAB 

REDITUX RA  Is From Company Dr. Reddy’S Priced :: Rs. 79,992.00

REDITUX RA have RITUXIMAB is comes under Sub class Drugs for Arthritis,Osteoporosis of  Main Class Musculoskeletal Disorders , Pain

Main Medicine Class:: Musculoskeletal Disorders , Pain  Sub Medicine Class :: Drugs for Arthritis,Osteoporosis 

Indications for Drugs ::

Non-Hodgkin’s lymphoma; follicular lymphoma

Drug Dose ::

Adult: IV Non-Hodgkin’s lymphoma; Refractory or relapsed follicular lymphoma As a single agent: 375 mg/m2 via infusion at 50 mg/hr once wkly for 4 doses. May increase rate slowly. If tolerated, may start subsequent infusions at 100 mg/hr and increase slowly. Max rate: 400 mg/hr. W/ cyclophosphamide, vincristine, and prednisolone for follicular lymphoma (CVP) or w/ cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for diffuse large B-cell lymphoma: 375 mg/m2 on day 1 of each 21-day cycle for 8 doses. Patients who were treated w/ 6-8 cycles of CVP chemotherapy and have not progressed: May give 375 mg/m2 once wkly for 4 doses, may repeat 6 mthly up to 16 doses. Maintenance for responders to induction chemotherapy: 375 mg/m2 once 3 mthly until disease progression or a max period of 2 yr. Rheumatoid arthritis Two 1g infusion doses, separated by 2 wk.

Contraindication ::

Lactation. Type I hypersensitivity or anaphylactic reactions to murine proteins or component of the formulation.

Drug Precautions ::

Extensive tumor burden, pulmonary tumor infiltration or pulmonary insufficiency; history of cardiac disease; effective contraception during and up to 12 mth after treatment; pregnancy. Monitor CBC and platelet counts regularly. Premedication with analgesics, antihistamines and corticosteroids may be recommended. Monitor for signs of active infection or hepatitis in hepatitis B carriers. Discontinue treatment if viral hepatitis develops.

Drug Side Effects ::

Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, tumor lysis syndrome, respiratory failure, thrombocytopenia, neutropenia, anaemia. Hypersensitivity reactions. Potentially Fatal: Pulmonary or cardiac toxicity during infusion; severe mucocutaneous reactions; severe cytokine release syndrome associated with tumor lysis syndrome. Toxic epidermal necrolysis.

Pregnancy category ::

3

Drug Mode of Action ::  

Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.

Drug Interactions ::

Increased risk of renal toxicity w/ cisplatin. Potentially Fatal: May decrease the efficacy of vaccines and increase the risk of infections in patients immunised w/ live vaccines.